|
 Auvi-Q, designed to deliver the same epinephrine drug as Mylan NV's
EpiPen, was recalled from the market last year amid concerns about
accuracy of the dosage delivered.
French pharmaceutical company Sanofi SA had licensed and made Auvi-Q,
but it returned rights to the product to Kaleo in February after the
recall.
Mylan has come under fire from lawmakers and consumer groups for
raising the list price for a pair of EpiPens to more than $600 this
year from $100 in 2007 when Mylan acquired the product.
Mylan said last month it plans to launch, at a list price of $300,
its own generic EpiPen by the end of this year.
Officials at Kaleo declined to comment on a planned list price for
the relaunched Auvi-Q.
"We are working on what is the right price to assure that the
ultimate patient co-pay is low," Kaleo Chief Executive Officer
Spencer Williamson told Reuters in a telephone interview.
Unlike the pen-shaped EpiPen, Auvi-Q, which includes a voice prompt
system to guide users, is the length and width of a credit card with
the thickness of a small cellphone.
The Kaleo device also has a needle that automatically retracts after
the device has been used.
[to top of second column] |
Williamson said Auvi-Q will be manufactured at an automated robotic
production line located in the Midwestern United States.
Kaleo also sells Evzio, a hand-held device designed to automatically
deliver a set dose of naloxone, a drug approved to treat an overdose
of opioid painkillers.
Evzio has a current list price of $3,750 for two active devices and
one training device.
(Reporting by Deena Beasley in Los Angeles; Editing by Cynthia
Osterman)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
